CN116437955A - 用于治疗ox40相关疾病的方法 - Google Patents

用于治疗ox40相关疾病的方法 Download PDF

Info

Publication number
CN116437955A
CN116437955A CN202180068736.0A CN202180068736A CN116437955A CN 116437955 A CN116437955 A CN 116437955A CN 202180068736 A CN202180068736 A CN 202180068736A CN 116437955 A CN116437955 A CN 116437955A
Authority
CN
China
Prior art keywords
weeks
antibody
administration
atopic dermatitis
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180068736.0A
Other languages
English (en)
Chinese (zh)
Inventor
佐藤光男
永田吉范
大泷显司
今井信行
岛边宗健
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of CN116437955A publication Critical patent/CN116437955A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180068736.0A 2020-10-09 2021-10-08 用于治疗ox40相关疾病的方法 Pending CN116437955A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063089809P 2020-10-09 2020-10-09
US63/089809 2020-10-09
US202063116365P 2020-11-20 2020-11-20
US63/116365 2020-11-20
US202163233592P 2021-08-16 2021-08-16
US63/233592 2021-08-16
PCT/JP2021/037481 WO2022075476A1 (en) 2020-10-09 2021-10-08 Method for treating ox40 related disease

Publications (1)

Publication Number Publication Date
CN116437955A true CN116437955A (zh) 2023-07-14

Family

ID=81126528

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180068736.0A Pending CN116437955A (zh) 2020-10-09 2021-10-08 用于治疗ox40相关疾病的方法

Country Status (11)

Country Link
US (1) US20230383001A1 (https=)
EP (1) EP4225371A4 (https=)
JP (1) JP2023545084A (https=)
KR (1) KR20230084166A (https=)
CN (1) CN116437955A (https=)
AU (1) AU2021358274A1 (https=)
CA (1) CA3198414A1 (https=)
IL (1) IL301935A (https=)
MX (1) MX2023004113A (https=)
TW (1) TW202222343A (https=)
WO (1) WO2022075476A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025021131A1 (en) * 2023-07-25 2025-01-30 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Methods of treating alopecia areata and atopic dermatitis

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025244002A1 (ja) * 2024-05-21 2025-11-27 国立大学法人京都大学 ベンダムスチンによるｔ細胞の減少を抑制するために使用されるｔ細胞減少抑制剤
WO2025259719A1 (en) * 2024-06-10 2025-12-18 Walden Biosciences, Inc. Method of administering an anti-soluble urokinase plasominogen activator receptor antibody for the treatment of kidney disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
WO2017134292A1 (en) * 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
PT3528838T (pt) * 2016-09-23 2023-09-04 Hoffmann La Roche Utilizações de antagonistas de il-13 para tratamento de dermatite atópica
WO2019229155A1 (en) * 2018-05-31 2019-12-05 Glenmark Pharmceuticals S.A. Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025021131A1 (en) * 2023-07-25 2025-01-30 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Methods of treating alopecia areata and atopic dermatitis

Also Published As

Publication number Publication date
AU2021358274A9 (en) 2024-05-30
TW202222343A (zh) 2022-06-16
IL301935A (en) 2023-06-01
EP4225371A1 (en) 2023-08-16
AU2021358274A1 (en) 2023-05-25
JP2023545084A (ja) 2023-10-26
KR20230084166A (ko) 2023-06-12
WO2022075476A1 (en) 2022-04-14
EP4225371A4 (en) 2024-11-20
MX2023004113A (es) 2023-06-29
CA3198414A1 (en) 2022-04-14
US20230383001A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
TWI699212B (zh) 藉由投與ｉｌ-４ｒ拮抗劑治療異位性皮膚炎的方法
CN112153982A (zh) 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
CN114173816A (zh) 通过施用il-4r拮抗剂治疗特应性皮炎的方法
CN116437955A (zh) 用于治疗ox40相关疾病的方法
US20240059783A1 (en) Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
CN109963577A (zh) 用于通过施用il-4r抑制剂治疗严重特应性皮炎的方法
JP2022028788A (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
US20250011417A1 (en) Methods for the treatment of thyroid eye disease
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
KR20240004367A (ko) 중증근무력증 치료를 위한 항-cd19 항체의 사용
TWI790457B (zh) 藉由投與il-4r拮抗劑治療異位性皮膚炎的方法
WO2025214333A1 (zh) 抗tslp抗体治疗与tslp相关的炎症疾病的方法
WO2025106642A1 (en) Methods for the treatment of thyroid eye disease
KR20250075690A (ko) 비활성 또는 만성 갑상선 눈 질환의 치료 방법
TW202535463A (zh) Ａｎｃａ相關血管炎之治療
KR20250135238A (ko) 면역 매개 괴사성 근병증의 치료 및 예방을 위한 항-cd19 결합제
US20250340665A1 (en) Methods of treating dermatomyositis
JP2023504679A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して扁平苔癬を治療する方法
JP2024516019A (ja) 抗ｂａｆｆｒ抗体を使用する全身性エリテマトーデスのための治療
CN108473576A (zh) 用于治疗复发形式的多发性硬化的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination